The question on many minds among FDA rank-and-file in attendance was: Which Prasad would show up? The 2010s Prasad -- a ...

In his new role with the FDA, Dr. Vinay Prasad will oversee the regulation of costly drugs, including vaccines, gene ...

CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...

WASHINGTON — In his first address to FDA staff on Wednesday, Vinay Prasad emphasized his commitment to evidence, his ...

The UCSF professor and frequent YouTube poster has criticized COVID-19 vaccine mandates as well as the accelerated approval ...

This is the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and ...

Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.

Biotech venture capital is risky business, inherently at the mercy of regulators and binary outcomes. Now it may face a new ...

The FDA's decision to appoint Vinay Prasad, MD, MPH, to head its Center for Biologics Evaluation and Research (CBER) raised ...

The US Food and Drug Administration has chosen Dr Vinay Prasad, a professor at the University of California-San Francisco, to lead its Center for Biologics Evaluation and Research.

Vinay Prasad, named to lead the FDA agency tasked with regulating vaccines and gene therapy, has made controversial comments ...

The appointment, announced May 6 by FDA Commissioner Dr. Marty Makary, places Prasad at the helm of one of the agency’s most ...